drugset
drugset / Trial / NCT03275558

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

NCT03275558 ↗

Phase 1 Withdrawn Center Trials & Treatment
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma, Gliosarcoma,Anaplastic Gliomas, Previously Treated). All drugs target the inhibition of the growth factors and neo-angiogenesis as one the main reasons for the growth of the tumor. The purpose of the Nasal Spray NST-4G study is to determine the safety and tolerability in order to establish the best dose level to be used in future studies.

Timeline

Start
2018-07-17
Primary completion
2018-07-17
Completion
2018-07-17

Outcome

Outcome not reported

Stopped (Enrollment): “Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Axitinib Small molecule 1 mg Intranasal
Comparator Pazopanib Small molecule 5 mg Intranasal
Comparator Sunitinib Small molecule 5 mg Intranasal

Indications

gliosarcoma